We find that the genome-wide GBM pattern of CNAs is statistically a better predictor of astrocytoma outcome, corresponding to greater median survival time difference, proportional hazard ratio, and concordance index, than MGMT promoter methylation and IDH1 mutation (Fig 8). The gene discussed is MGMT; the disease is astrocytoma (excluding glioblastoma).